Comparison of ROCK and EGFR activation pathways in the progression of glomerular injuries in AngII-infused rats

Renal Failure

Volumn 33, Issue 10, 2011, Pages 1005-1012

  Suzuki, Hiroyuki ^a   Yamamoto, Tatsuo ^a   Fujigaki, Yoshihide ^a   Eguchi, Satoru ^b   Hishida, Akira ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Epidermal growth factor receptor; Glomerular injuries; Hypertension; Rho kinase (ROCK)

Indexed keywords

ANGIOTENSIN II; CYCLIN D1; CYCLINE; FASUDIL; GEFITINIB; KI 67 ANTIGEN; NEPHRIN; PODOCIN; PROTEIN P27; RHO KINASE; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DRUG INHIBITION; GLOMERULAR CELL PROLIFERATION; GLOMERULUS INJURY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; MALE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; URINARY EXCRETION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANGIOTENSIN II; ANIMALS; DISEASE PROGRESSION; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RATS; RATS, WISTAR; RECEPTOR, EPIDERMAL GROWTH FACTOR; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 80054954517     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.618923     Document Type: Article

References (37)

1. Ohashi N, Yamamoto T, Huang Y, et al. Intrarenal RAS activity and urinary angiotensinogen excretion in antithymocyte serum nephritis rats. Am J Physiol Renal Physiol. 2008;295(5):F1512-F1518.
2. Yamamoto T, Nakagawa T, Suzuki H, et al. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol. 2007;18(5):1558-1565. (Pubitemid 46717523)
3. Suzuki H, Yamamoto T, Ikegaya N, Hishida A. Dietary salt intake modulates progression of antithymocyte serum nephritis through alteration of glomerular angiotensin II receptor expression. Am J Physiol Renal Physiol. 2004;286(2):F267-F277. (Pubitemid 38141670)
4. Suzuki H, Motley ED, Frank GD, Utsunomiya H, Eguchi S. Recent progress in signal transduction research of the angiotensin II type-1 receptor: Protein kinases, vascular dysfunction and structural requirement. Curr Med Chem Cardiovasc Hematol Agents. 2005;3(4):305-322. (Pubitemid 41264268)
5. Nishikimi T, Akimoto K, Wang X, et al. Fasudil, a rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens. 2004;22(9):1787-1796. (Pubitemid 39141972)
6. Kanda T, Wakino S, Hayashi K, Homma K, Ozawa Y, Saruta T. Effect of fasudil on rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int. 2003;64(6):2009-2019. (Pubitemid 37449535)
7. Nishikimi T, Koshikawa S, Ishikawa Y, et al. Inhibition of rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. J Hypertens. 2007;25(5):1053-1063. (Pubitemid 46573125)
8. Ohtsu H, Suzuki H, Nakashima H, et al. Angiotensin II signal transduction through small GTP-binding proteins: Mechanism and significance in vascular smooth muscle cells. Hypertension. 2006;48(4):534-540. (Pubitemid 44843847)
9. Suzuki H, Frank GD, Utsunomiya H, Higuchi S, Eguchi S. Current understanding of the mechanism and role of ROS in angiotensin II signal transduction. Curr Pharm Biotechnol. 2006;7(2):81-86. (Pubitemid 44110354)
10. Lautrette A, Li S, Alili R, et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: A new therapeutic approach. Nat Med. 2005;11(8):867-874. (Pubitemid 41161119)
11. Nakopoulou L, Stefanaki K, Boletis J, et al. Immunohistochemical study of epidermal growth factor receptor (EGFR) in various types of renal injury. Nephrol Dial Transplant. 1994;9(7):764-769. (Pubitemid 24209755)
12. Ding G, Zhang A, Huang S, et al. ANG II induces c-Jun NH2-terminal kinase activation and proliferation of human mesangial cells via redox-sensitive transactivation of the EGFR. Am J Physiol Renal Physiol. 2007;293(6): F1889-F1897. (Pubitemid 350179613)
13. Flannery PJ, Spurney RF. Transactivation of the epidermal growth factor receptor by angiotensin II in glomerular podocytes. Nephron Exp Nephrol. 2006;103(3): e109-e118. (Pubitemid 43952616)
14. Wolf G, Wenzel UO. Angiotensin II and cell cycle regulation. Hypertension. 2004;43(4):693-698. (Pubitemid 38405570)
15. Ardaillou R, Chansel D, Chatziantoniou C, Dussaule JC. Mesangial AT1 receptors: Expression, signaling, and regulation. J Am Soc Nephrol. 1999;10(Suppl. 11):S40-S46.
16. Izevbigie EB, Gutkind JS, Ray PE. Angiotensin II and basic fibroblast growth factor mitogenic pathways in human fetal mesangial cells. Pediatr Res. 2000;47(5):614-621. (Pubitemid 30249849)
17. Ishikawa Y, Nishikimi T, Akimoto K, Ishimura K, Ono H, Matsuoka H. Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension. 2006;47(6):1075-1083. (Pubitemid 44289164)
18. Polyak K, Lee MH, Erdjument-Bromage H, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994;78(1):59-66.
19. Sawada N, Itoh H, Ueyama K, et al. Inhibition of rhoassociated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation. 2000;101(17):2030-2033. (Pubitemid 30233164)
20. Kanda T, Hayashi K, Wakino S, et al. Role of rho-kinase and p27 in angiotensin II-induced vascular injury. Hypertension. 2005;45(4):724-729. (Pubitemid 40418372)
21. Diez-Juan A, Andres V. The growth suppressor p27(Kip1) protects against diet-induced atherosclerosis. FASEB J. 2001;15(11):1989-1995. (Pubitemid 32848803)
22. DAlessio A, De Luca A, Maiello MR, et al. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast Cancer Res Treat. 2010;123(2): 387-396.
23. Nose A, Mori Y, Uchiyama-Tanaka Y, et al. Regulation of glucose transporter (GLUT1) gene expression by angiotensin II in mesangial cells: Involvement of HB-EGF and EGF receptor transactivation. Hypertens Res. 2003;26(1): 67-73. (Pubitemid 36193101)
24. Perlman A, Lawsin LM, Kolachana P, Saji M, Moore Jr., J, Ringel MD. Angiotensin II regulation of TGF-beta in murine mesangial cells involves both PI3 kinase and MAP kinase. Ann Clin Lab Sci. 2004;34(3):277-286. (Pubitemid 39166990)
25. Diep QN, ElMabrouk M, Touyz RM, Schiffrin EL. Expression of cell cycle proteins in blood vessels of angiotensin II-infused rats: Role of AT(1) receptors. Hypertension. 2001;37(2 Part 2):604-608. (Pubitemid 32199035)
26. Liu Y, Wen JK, Dong LH, Zheng B, Han M. Kruppel-like factor (KLF) 5 mediates cyclin D1 expression and cell proliferation via interaction with c-Jun in Ang II-induced VSMCs. Acta Pharmacol Sin. 2009;31(1):10-18.
27. Morikawa-Futamatsu K, Adachi S, Maejima Y, et al. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1. Life Sci. 2006;79(14): 1380-1390. (Pubitemid 44215930)
28. Kawachi H, Koike H, Kurihara H, Sakai T, Shimizu F. Cloning of rat homologue of podocin: Expression in proteinuric states and in developing glomeruli. J Am Soc Nephrol. 2003;14(1): 46-56. (Pubitemid 36026296)
29. Kawachi H, Kurihara H, Topham PS, et al. Slit diaphragmreactive nephritogenic MAb 5-1-6 alters expression of ZO-1 in rat podocytes. Am J Physiol. 1997;273(6 Pt 2):F984-F993.
30. Shibata S, Nagase M, Fujita T. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol. 2006;17(3): 754-764.
31. Whaley-Connell A, Habibi J, Nistala R, et al. Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension. 2008;51(2):474-480. (Pubitemid 351156435)
32. Suzuki K, Han GD, Miyauchi N, et al. Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall. Am J Pathol. 2007;170(6):1841-1853. (Pubitemid 47339259)
33. Doublier S, Salvidio G, Lupia E, et al. Nephrin expression is reduced in human diabetic nephropathy: Evidence for a distinct role for glycated albumin and angiotensin II. Diabetes. 2003;52(4):1023-1030. (Pubitemid 36384273)
34. Fisher ND, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation. 2008;117(25):3199-3205.
35. Wang L, Ellis MJ, Fields TA, Howell DN, Spurney RF. Beneficial effects of the Rho kinase inhibitor Y27632 in murine puromycin aminonucleoside nephrosis. Kidney Blood Press Res. 2008;31(2):111-121. (Pubitemid 351630068)
36. Menne J, Meier M, Park JK, et al. Nephrin loss in experimental diabetic nephropathy is prevented by deletion of protein kinase C alpha signaling in-vivo. Kidney Int. 2006;70(8): 1456-1462. (Pubitemid 44527315)
37. Ohtsu H,Mifune M, Frank GD, et al. Signal-crosstalk between Rho/ROCK and c-Jun NH2-terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II. Arterioscler Thromb Vasc Biol. 2005;25(9):1831-1836. (Pubitemid 41243450)